By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Drugs > Plasma protein fraction (monograph) > Plasma Protein Fraction Dosage
Drugs
https://themeditary.com/dosage-information/plasma-protein-fraction-dosage-8856.html

Plasma Protein Fraction Dosage

Drug Detail:Plasma protein fraction (monograph) (Medically reviewed)

Drug Class:

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Shock

Replacement of coagulation factors in patients with acquired deficiencies:

  • Initially infuse of 10 to 15 mL/kg; this should increase the patient's plasma coagulation factor levels by approximately 15% to 25%; if hemostasis is not achieved, use higher doses
  • Adjust dose based on desired response.

Plasma exchange in patients with TTP:
  • Completely replace plasma volume removed during plasmapheresis; generally, 1 to 1.5 plasma volumes correspond to 40 to 60 mL/kg

Comments:
  • Administer this drug based on ABO-blood group compatibility.
  • Dose should be based on the individual patient and response to therapy.
  • Rate should be adjusted or slowed according to clinical response and rising blood pressure.

Uses: Replacement of multiple coagulation factors in patients with acquired deficiencies due to liver disease, undergoing cardiac surgery and liver transplantation, or plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP)

Usual Pediatric Dose for Shock

Replacement of coagulation factors in patients with acquired deficiencies:

  • Initially infuse of 10 to 15 mL/kg; this should increase the patient's plasma coagulation factor levels by approximately 15% to 25%; if hemostasis is not achieved, use higher doses
  • Adjust dose based on desired response.

Plasma exchange in patients with TTP:
  • Completely replace plasma volume removed during plasmapheresis; generally, 1 to 1.5 plasma volumes correspond to 40 to 60 mL/kg

Comments:
  • Administer this drug based on ABO-blood group compatibility.
  • Dose should be based on the individual patient and response to therapy.
  • Rate should be adjusted or slowed according to clinical response and rising blood pressure.

Uses: Replacement of multiple coagulation factors in patients with acquired deficiencies due to liver disease, undergoing cardiac surgery and liver transplantation, or plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP)

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

  • Hypersensitivity to the active component or any of the ingredients
  • Hypersensitivity to fresh frozen plasma (FFP) or to plasma-derived products including any plasma protein
  • IgA deficiency
  • Severe deficiency of Protein S (5)

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Administer this drug based on ABO-blood group compatibility.
  • Administer this drug after thawing using an infusion set with a filter.
  • This drug should be administered by IV infusion after thawing.
  • After thawing the solution is clear to slightly opalescent and free of solid or gelatinous particles.
  • Citrate toxicity can occur when more than 0.02 to 0.025 mmol citrate per kg per minute is administered; therefore, the infusion rate should not exceed 1 mL/min.
  • Toxic effects of citrate can be minimized by giving calcium gluconate iv into another vein.

Storage requirements:
  • Store at -18C (-0.4F) for 3 years from the date of manufacture.
  • Protect from light.

Reconstitution/preparation techniques:
  • Thaw product according to instructions in the manufacturer product information.
  • Use thawed product within 24 hours.
  • Do not refreeze thawed product.
  • The manufacturer product information should be consulted.

General:
  • Solutions that are turbid should not be used.
  • Solutions that have been frozen should not be used.
  • Administration should not begin more than 4 hours after the container has been entered.
  • Partially used or previous entered vials should be discarded.
Share this Article
Latest News
Medical News

Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk

Jun 01, 2025
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Heart health: Exercise not enough to offset effects of poor sleep
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by